Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linsitinib Rollover Study
NCT02057380Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Apr 2014
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label trial of linsitinib in solid tumor (advanced stage), adrenocortical carcinoma (ACC), non-small cell lung cancer (NSCLC) and 4 more (12 arms), sponsored by Astellas Pharma. Primary endpoint: Number of subjects with adverse events at 24 months. Started Apr 2014; status: completed.
02
Drugs
linsitinib
03
Conditions
solid tumor (advanced stage)adrenocortical carcinoma (ACC)non-small cell lung cancer (NSCLC)ovarian cancergastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT02057380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02057380.